22NW LP Increases Stock Holdings in Nektar Therapeutics $NKTR

22NW LP raised its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 126.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 331,115 shares of the biopharmaceutical company’s stock after purchasing an additional 185,000 shares during the quarter. Nektar Therapeutics makes up approximately 9.8% of 22NW LP’s portfolio, making the stock its 3rd largest holding. 22NW LP owned 1.63% of Nektar Therapeutics worth $18,840,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of Nektar Therapeutics by 336.9% during the 1st quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock valued at $2,463,000 after buying an additional 2,807,595 shares in the last quarter. Vanguard Group Inc. grew its stake in Nektar Therapeutics by 30.0% in the 3rd quarter. Vanguard Group Inc. now owns 948,647 shares of the biopharmaceutical company’s stock valued at $53,978,000 after buying an additional 219,155 shares in the last quarter. Two Sigma Investments LP raised its holdings in Nektar Therapeutics by 446.9% during the 3rd quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock valued at $24,708,000 after acquiring an additional 354,842 shares during the period. Emerald Advisers LLC bought a new position in shares of Nektar Therapeutics in the third quarter worth $18,393,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Nektar Therapeutics in the third quarter worth $17,252,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Stock Up 4.1%

Shares of NASDAQ NKTR opened at $73.25 on Friday. The stock’s 50-day simple moving average is $53.50 and its two-hundred day simple moving average is $53.23. Nektar Therapeutics has a twelve month low of $6.45 and a twelve month high of $77.00. The firm has a market capitalization of $1.49 billion, a P/E ratio of -7.18 and a beta of 1.17.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.69) by $0.91. The firm had revenue of $21.81 million during the quarter, compared to the consensus estimate of $10.44 million. Nektar Therapeutics had a negative return on equity of 638.32% and a negative net margin of 297.07%. As a group, research analysts anticipate that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.

More Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations: EPS loss of ($1.78) topped consensus and revenue of $21.8M substantially exceeded estimates; management highlighted promising clinical data and near-term plans for rezpeg Phase III studies in atopic dermatitis (timing noted for Q2 2026). Nektar Reports Fourth-Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Earnings call and analyst coverage reinforced the upside: call transcripts and press coverage flagged promising Phase 2b/clinical takeaways that appear to be driving bullish investor sentiment and volume today. Earnings Call Transcript
• Neutral Sentiment: Balance-sheet snapshot: cash and marketable securities were $245.8M at year-end (down from $269.1M a year earlier) — provides runway but still limited given development-stage spending; watch cash burn guidance and upcoming Phase III cost needs. Financial Results / Cash Position
• Negative Sentiment: Multiple law firms have filed or announced securities-fraud investigations and class action notices covering the Feb 26–Dec 15, 2025 period; several firms are soliciting lead-plaintiff motions with a May 5, 2026 deadline — litigation could lead to legal costs, management distraction and settlement risk. Rosen Law Firm Notice Pomerantz Filing

Insider Buying and Selling

In other news, insider Jonathan Zalevsky sold 3,867 shares of Nektar Therapeutics stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total transaction of $137,935.89. Following the completion of the sale, the insider directly owned 21,354 shares of the company’s stock, valued at approximately $761,697.18. The trade was a 15.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Howard W. Robin sold 423 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the transaction, the chief executive officer owned 75,489 shares of the company’s stock, valued at $5,510,697. This trade represents a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 4,470 shares of company stock valued at $181,955. Corporate insiders own 5.25% of the company’s stock.

Analyst Upgrades and Downgrades

NKTR has been the topic of a number of analyst reports. William Blair upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nektar Therapeutics in a report on Monday, December 29th. Citigroup initiated coverage on Nektar Therapeutics in a research report on Wednesday, November 26th. They set a “buy” rating and a $102.00 price target on the stock. B. Riley Financial reissued a “buy” rating and issued a $150.00 price target (up from $105.00) on shares of Nektar Therapeutics in a report on Monday, February 23rd. Finally, HC Wainwright raised their price objective on shares of Nektar Therapeutics from $135.00 to $165.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $133.43.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.